# K061970

# 510(k) Summary - Elecsys IgE II Immunoassay

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence

# Submitter name, address, contact

Roche Diagnostics 9115 Hague Rd Indianapolis IN 46250 (317) 521-3544

Contact person: Kay A. Taylor

Date prepared: July 11, 2006

# Device Name

Proprietary name: Elecsys IgE II immunoassay

Common name: IgE test

Classification name: radioimmunoassay, immunoglobulins (d, e)

# Device description

The Elecsys IgE II immunoassay is a two step sandwich immunoassay with streptavidin microparticles and electrochemiluminescence detection. Results are determined using a calibration curve that is generated specifically on each instrument by a 2 point calibration and a master curve provided with the reagent bar code.

# Intended Use / Indications for Use

Immunoassay for the in vitro quantitative determination of immunoglobulin E in human serum and plasma. Determination of total IgE is useful as an aid in the diagnosis of allergic diseases.

# Substantial equivalence

The Elecsys IgE II immunoassay is substantially equivalent to another device legally marketed in the United States. Elecsys IgE II (modified) assay is equivalent to the Elecsys IgE immunoassay (K984326, K961481/A003). Both products are intended for use in the quantitative determination of IgE in serum and plasma.

# Device Comparison

# 510(k) Summary - Elecsys IgE Il Immunoassay, continued

<table><tr><td rowspan=1 colspan=1>Topic</td><td rowspan=1 colspan=1>Elecsys IgE (K984326,K961481/A003)</td><td rowspan=1 colspan=1>Elecsys IgE II (Modified Device)</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Immunoassay for the in vitroquantitative determination ofimmunoglobulin E in human serumand plasma. Determination of totalIgE is useful as an aid in the diagnosisof allergic diseases.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Analyzers</td><td rowspan=1 colspan=1>Roche Elecsys 1010/2010 andMODULAR ANALYTICS E170(Elecsys module) immunoassayanalyzers.</td><td rowspan=1 colspan=1>Roche Elecsys 2010 and MODULARANALYTICS E170 (Elecsys module)immunoassay analyzers.</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>Assay standardized against the 2ndIRPWHO Reference Standard 75/502</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Protocol</td><td rowspan=1 colspan=1>Sandwich</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum and plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibrator,CalibrationVerification &amp;Controls</td><td rowspan=1 colspan=1>IgE CalSetIgE CalCheckPreciControl Universal</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>MeasuringRange</td><td rowspan=1 colspan=1>0.10 - 2500 IU/ml</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>AnalyticalSensitivity</td><td rowspan=1 colspan=1>0.10 IU/ml</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>FunctionalSensitivity</td><td rowspan=1 colspan=1>0.50 IU/ml</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Composition</td><td rowspan=1 colspan=1>R1: 2.4 mg/L AB-Bi, buffer,preservativeR2: 4.8 mg/L AB-Ru, buffer,preservativeM: 0.72 mg/ml streptavidin-coatedmicroparticles, preservative</td><td rowspan=1 colspan=1>R1: 2.5 mg/L (mono-Bi)AB-Bi,buffer, preservativeR2: 5.5 mg/L AB-Ru, buffer,preservativeM: 0.72 mg/ml streptavidin-coatedmicroparticles, preservative</td></tr><tr><td rowspan=1 colspan=1>DilutionRecommendation</td><td rowspan=1 colspan=1>Concentration of diluted samples mustbe &gt; 60 IU/mL</td><td rowspan=1 colspan=1>Concentration of diluted samples mustbe &gt; 125 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Interferences</td><td rowspan=1 colspan=1>No affect up to,bilirubin &lt; 37 mg/dlhemoglobin &lt; 1.1 g/dltriglycerides &lt; 2200 mg/dlbiotin &lt; 100 ng/ml</td><td rowspan=1 colspan=1>No affect up to,Bilirubin - Samehemoglobin &lt; 0.1 g/dltriglycerides - Samebiotin - Same</td></tr></table>

# 510(k) Summary - Elecsys IgE II Immunoassay, continued

<table><tr><td>Topic</td><td colspan="2">Elecsys IgE (K984326, K961481/A003)</td><td colspan="2">Elecsys IgE II (Modified Device)</td></tr><tr><td>Precision</td><td colspan="2">Elecsys 1010 / 2010:</td><td colspan="2">Elecsys 2010:</td></tr><tr><td></td><td colspan="2">Intra-assay</td><td colspan="2">Intra-assay:</td></tr><tr><td rowspan="10"></td><td>HS1 3.6% CV @</td><td>5.18 IU/mL</td><td>HS1 4.1% CV @</td><td>32.7 IU/mL</td></tr><tr><td>HS2 3.2% CV @</td><td>398 IU/mL</td><td>HS2 2.4% CV @</td><td>265 IU/mL</td></tr><tr><td>HS3 2.4% CV @</td><td>1010 IU/mL</td><td>HS3 2.6% CV @</td><td>1295 IU/mL</td></tr><tr><td>Total:</td><td></td><td></td><td></td></tr><tr><td>HS1 4.2% CV @</td><td>5.18 IU/mL</td><td>Total: HS1 5.1% CV @</td><td>32.7 IU/mL</td></tr><tr><td>HS2 3.9% CV @</td><td>398 IU/mL</td><td>HS2 3.8% CV @</td><td>265 IU/mL</td></tr><tr><td>HS3 3.1% CV @</td><td>1010 IU/mL</td><td>HS3 3.9% CV @</td><td>1295 IU/mL</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td>E170:</td><td>E170:</td><td></td><td></td></tr><tr><td>Intra-assay</td><td></td><td>Intra-assay:</td><td></td></tr><tr><td>HS1 2.3% CV @</td><td>3.36 IU/mL</td><td>HS1 1.4% CV @</td><td>4.4 IU/mL</td></tr><tr><td>HS2 2.2% CV @ HS3 2.6% CV @</td><td>457 IU/mL</td><td>HS2 0.7% CV @</td><td>261 IU/mL</td></tr><tr><td></td><td>1128 IU/mL</td><td>HS3 1.0% CV @</td><td>1018 IU/mL</td></tr><tr><td>Total:</td><td></td><td>Total:</td><td></td></tr><tr><td>HS1 4.3% CV @</td><td>3.31 IU/mL</td><td>HS1 2.7% CV @</td><td>30.2 IU/mL</td></tr><tr><td>HS2 3.8% CV @</td><td>443 IU/mL</td><td>HS2 2.8% CV @</td><td>245 IU/mL</td></tr><tr><td>HS3 6.5% CV @</td><td>1215 IU/mL</td><td>HS3 3.4% CV @</td><td>1207 IU/mL</td></tr></table>

Ms. Kay A. Taylor, MT (ASCP), RAC Regulatory Affairs Principal   
US Regulatory Affairs   
Roche Diagnostics, Inc.   
9115 Hague Road   
P.O. Box 50416   
Indianapolis, Indiana 46250-0416

# AUG 3 1 2006

Re: k061970 Trade/Device Name: Elecsys IgE II Immunoassay Regulation Number: 21 CFR $\$ 866.5510$ EMPY Regulation Name: Immunoglobulins A, G, M, D and E Immunological Test System Regulatory Class: II Product Code: JHR Dated: August 22, 2006 Received: August 23, 2006

Dear Ms. Taylor:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations afecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2 -

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html

Sincerely yours,

![](images/6a15013e824242f5708408502d556939a051bdef088d26f9925314bb7d0ed82c.jpg)

Robert L. Becker, Jr., MD, PK.D   
Director   
Division of Immunology and Hematology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indications for Use

510(k) Number (if known): K061970

Device Name: Elecsys IgE II Immunoassay

Indications For Use:

Immunoassay for the in vitro quantitative determination of immunoglobulin E in human serum and plasma.

Determination of total IgE is useful as an aid in the diagnosis of allergic diseases.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on the Roche Elecsys 2010 and MODULAR ANALYTICS E170   
(Elecsys module) immunoassay analyzers.